• In early January 2026, Moderna reported positive Phase 3 data and submitted regulatory applications in the U.S., EU, Canada, and Australia for its mRNA-1010 seasonal flu vaccine for adults aged 50 and over.
• This move highlights Moderna’s effort to broaden its respiratory vaccine lineup beyond COVID-19, aiming to reduce dependence on a single product category and make fuller use of its mRNA platform.
• We’ll now examine how this progress on mRNA-1010, and its potential to diversify respiratory revenues, affects Moderna’s investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Moderna Investment Narrative Recap

To own Moderna today, you need to believe its mRNA platform can support a broader portfolio that eventually steadies revenues beyond COVID‑19 boosters. The mRNA‑1010 flu filings are helpful for future diversification, but they do not change the near term picture where the key catalyst remains execution on respiratory launches, while the biggest risk is that seasonal vaccine demand and pricing keep revenue volatile and profits elusive.

Among recent updates, Moderna’s November 2025 term loan with Ares Capital stands out. The US$1.5 billion facility gives the company additional liquidity as it pushes vaccines like mRNA‑1010 through regulatory review, but also underlines how dependent Moderna is on external capital while it works toward cash breakeven and more durable non‑COVID revenue streams.

Yet behind the flu progress, investors should be aware of ongoing revenue volatility tied to seasonal respiratory demand and...

Moderna's narrative projects $3.5 billion revenue and $498.6 million earnings by 2028. This requires 4.6% yearly revenue growth and about a $3.4 billion earnings increase from -$2.9 billion today.

Uncover how Moderna's forecasts yield a $36.75 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Twenty four Simply Wall St Community valuations span from US$36.60 to US$175, showing just how far apart investor expectations can be. Before you align with any one view, consider how much of Moderna’s future still hinges on seasonal respiratory vaccines that may leave cash flows uneven for longer than some forecasts assume.

Explore 24 other fair value estimates on Moderna - why the stock might be worth just $36.60!

Build Your Own Moderna Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.